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Background: The human immunodeficiency virus (HIV) 
is the causative agent of acquired immunodeficiency syn- 
drome (AIDS). Two subtypes of the virus, HIV-1 and 
HIV-2, have been characterized. The protease enzymes 
from these two subtypes, which are aspartic acid proteases 
and have been found to be essential for maturation of the 
infectious particle, share about 50% sequence identity. 
Differences in substrate and inhibitor binding between 
these enzymes have been previously reported. 
Results: We report the X-ray crystal structures of both 
HIV-1 and HIV-2 proteases each in complex with the 
pseudosymmetric inhibitor, CGP 53820, to 2.2 A and 
2.3 A, respectively. In both structures, the entire enzyme 
and inhibitor could be located. The structures confirmed 
earlier modeling studies. Differences between the 
CGP 53820 inhibitory binding constants for the two 
enzymes could be correlated with structural differences. 
Conclusions: Minor sequence changes in subsites at  the 
active site can explain some of the observed differences in 
substrate and inhibitor binding-between the two enzymes. 
The information gained from this investigation may help in 
the design of equipotent HIV-1 /HIV-2 protease inhibitors. 
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Introduction 
The human immunodeficiency virus type-1 (HIV-1) is 
the causative agent responsible for the development of 
acquired immunodeficiency syndrome (AIDS) [I-31. 
The closely related subtype HIV-2 (41 was first identified 
in West Africa, but is now reported to be widespread in 
other parts of the world. The human immunodeficiency 
viruses belong to the retrovirus family and share a 
common genome organization. The gag gene of HIV 
encodes the structural proteins of the virus, whereas the 
pol gene encodes the enzymes essential for replication: 
reverse transcriptase, integrase and a protease. These 
genes are expressed as two polyproteins pr55 gag and the 
frameshifi product pr160 gag-pol. The protease encoded 
by HIV is essential for cleavage of the precursor proteins 
into individual structural proteins and enzymes during 
maturation of the virus [5,6]. Because the processing of 
the polyproteins has been shown to be indispensable for 
the assembly of infectious virus particles [7-91 the pro- 
tease is considered to be an attractive therapeutic target 
for the treatment of AIDS. 
The HIV protease belongs to the family of aspartyl pro- 
teases, which also includes renin and pepsin. It has been 
shown to consist of two identical peptide chains of 99 
amino acids each, which together form the active site of 
the enzyme. The structure of the protease from HIV-1 has 
been determined [10-131 and quite a number of structures 
of enzyme-inhibitor complexes have been published 
(reviewed in (1 4,151). Recently, structures of the HIV-2 
protease in complex with different inhibitors have also 
been published (16-181. HIV-1 and HIV-2 proteases dis- 
play approximately 50%) sequence identity (191 (Fig. 1) and 
similar substrate specificity [20]. Nevertheless, differences 
in thejr specificities have been demonstrated using peptide 
substr&es [21] and substrate analog inhibitors [16,22,23]. 
In order to identi$ the differences at high resolution and 
to try to understand these differences at the molecular 
level it is important to study the structures of HIV-1 and 
HIV-2 protease-inhibitor complexes. One approach used 
to design inhibitors of HIV protease has focused on syn- 
thetic peptide analogs that mimic the transition state (for 
review, see [14]). The C2-symmetry of the protease 
[lo-131 has led to the design of C2-symmetric inhibitors 
that are expected to provide a high degree of specificity for 
the viral enzyme. Various potent C2-symmetric inhibitors, 
which contain a hydroxyethylene core as a tetrahedral 
transition state analog, have been described (24-271. 
Their synthetic accessibility and broad variability, as well 
as indications from molecular modeling studies, have led 
to the exploration of a novel pseudosymmetric type of 
dipeptide, isostere, containing a hydroxyethyl hydrazine 
moiety as a possible inhibitor .compound. A series of 
potent HIV inhibitors with excellent antiviral activity 
and high specificity for HIV protease were subsequently 
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Fig. 1. Sequence alignment of the pro-
teases from HIV-1 (bru isolate) and
HIV-2 (rod isolate). The 48 identical
residues are boxed.
synthesized [28]. One representative, CGP 53820 (Fig.
2), has now been crystallized in complex with both
HIV-1 and HIV-2 protease. We describe a detailed com-
parison of the two structures and an analysis of the mole-
cular basis for the differences in binding of HIV-1 and
HIV-2 proteases.
Results and discussion
As expected, the overall fold and structure, as well as the
C2-symmetry, of the HIV-2 protease is very similar to that
of the HIV-1 protease. The main structural differences
between the two enzymes are concentrated in the outer
loops which show the highest degree of heterogeneity at
the amino acid sequence level (Fig. 3a). Most amino acid
differences are due to conservative changes such as the
common exchange Ile<-Val (Fig. 1). Of the residues that
directly line the active site, only residues 32, 47 and 82
differ between HIV-1 and HIV-2 protease and all three
are Ile<->Val exchanges. The central regions of both struc-
tures, including the dimer interface and the portions
forming the active-site cleft, are highly conserved (Fig.
3a). Both enzymes possess an active site, formed by two
monomers, that is very hydrophobic in nature. Each of
the two polypeptide chains in both enzymes provides one
catalytic aspartic acid residue (Asp25). Both aspartate side
chains are located on the inner floor and at the center of
the active-site cleft. The active site is covered by the two
flexible loops - the 'flaps' - consisting of the amino
acid residues 48-52 from both polypeptide chains. The
Fig. 2. The pseudosymmetrical HIV protease inhibitor
CGP 53820. Cha refers to the cyclohexyl 'side chain' which
binds in the P1' pocket of HIV protease.
sequence of the flap residues is identical in both HIV-1
and HIV-2 proteases, as are their conformations.
The asymmetric unit of the crystals of the complexes of
both HIV-1 and HIV-2 proteases with CGP 53820 con-
tains a dimer molecule. An analysis of the C 2-symmetry
relationship between the two identical polypeptide chains
in the HIV-1 and the HIV-2 protease structures can
therefore be performed. The relative orientation of the
two monomers to each other in the two enzymes is
slightly different. Optimal superposition of the Cot atoms
gives a molecular 'two-fold axis' of 178.4 ° for HIV-1
protease and 179.80 for HIV-2 protease. The root mean
square (rms) deviation of all Co atoms between superim-
posed monomers for HIV-1 is slightly larger (0.720 A)
than for HIV-2 (0.527 A). Of the two structures, the
HIV-2 protease structure seems to fulfil the two-fold
symmetry conditions better.
In both crystals, the pseudosymmetric inhibitor seems to
bind to the enzyme in a single orientation. This contrasts
with the findings of Mulichak et al. [16] who described
inhibitor binding in two opposite inhibitor orientations,
but is similar to the many complexes of HIV protease
with asymmetric inhibitors [14,15,18]. Furthermore, in
the structures described here, the two carbonyl and
amide orientations of the peptide bond between residue
50 and 51 at the B-turn of the flap show a single orienta-
tion with no static disorder, again in contrast to the
structures described by Mulichak et al. [16].
Fig. 3b documents the deviation from two-fold symme-
try of the loop region around residues 15-20 in HIV-1
protease as well as of the loop around residue 80, which
forms part of the active-site cleft pocket P1/P1'. The
glycines at residue 16 in the A- and B-chains have differ-
ent ,qs angles, which may have been induced by crystal
contacts. In the case of the loop around residue 80, the
different orientation can be attributed predominantly to
the interaction with the inhibitor. The overall two-fold
symmetry of the A- and B-chains is better preserved in
the HIV-2 protease structure.
Binding of CGP 53820 to the enzyme
The pseudosymmetric inhibitor CGP 53820 contains a
hydroxyethyl hydrazine moiety (Fig. 2) and binds to HIV
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Fig. 3. (a) Stereo illustration of the
superposition of the Ca atoms of HIV-1
protease (red) and HIV-2 protease (blue)
in complex with CGP 53820 (not
shown). The two catalytic aspartate
residues (shown in yellow) point
towards the active site which is closed
off by the two 'flaps' extending down
from the top of the A-chain and up from
the bottom of the B-chain. (b) Ca devia-
tions of the superimposed A-chain
(plain line) and B-chain (broken line) of
HIV-2 protease in complex with CGP
53820. The C -symmetry of the enzyme
is generally better maintained in the
complex with HIV-2 protease.
protease in an extended conformation. The hydroxyl
group of the peptide isostere is positioned symmetrically
between the two catalytic aspartate residues of the
enzyme active site. The phenyl and cyclohexyl groups
are accommodated in the P1 and P1' pockets, respec-
tively. The valine side chains occupy the P2/P2' binding
pockets. Table 1 lists the residues lining these active-site
specificity pockets. A tightly bound water molecule
bridges the amide nitrogen atoms of the Ile-A50 and
Ile-B50 residues in the flap of the enzyme and the two
carbonyl groups adjacent to the peptide 'mimic' in the
inhibitor. Potential hydrogen bonds between inhibitor
and enzyme are indicated in Table 2. In the symmetric
inhibitor, the peptide group between the Na of the P1'
cyclohexyl group and the Ct of the P2' valine is inverted
relative to the orientation in a peptide substrate.
Table 1. Residues lining the active-site pockets of HIV protease.
P2 P1 P1' P2'
lle-A50 Arg-A8 Gly-A27 Ala-A28
Ala-B28 Leu-A23 Gly-A49 Asp-A30
Asp-B30 Thr-A80 lle-A50 Val/lle-A32
Val/lle-B32 Pro-A81 Arg-B8 lle/Val-A47
lle/Val-B47 Val/lle-A82 Leu-B23 lle-A84
lle-B84 lle-A84 Thr-B80 lle-B50
Gly-B27 Pro-B81
Gly-B49 Val/lle-B82
lle-B50 lle-B84
Amino acid differences between HIV-1 and HIV-2 proteases are indi-
cated by slashes.
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Table 2. Potential hydrogen bonds between CGP53820 and the proteases
from HIV-1 and HIV-2.
CGP53820 HIV-1
Atom Atom
Hydroxyl of Phe-Cha
isoster
Carbonyl of P2 acetyl
Amide of P2 Val
Carbonyl of P2 Val
Amide of P1 Phe
Amide of PI' Cha
Carbonyl of P2' Val
Amide of P2' Val
Carbonyl of P2' acetyl
081 Asp-A25
082 Asp-A25
081 Asp-B25
082 Asp-B25
0 Gly-B27
N Asp-B29
0 Wat-8
0 Gly-B48
0 Wat-5
0 Gly-B27
0 Gly-A27
0 Wat-5
0 Gly-A48
N Asp-A29
0 Wat-4
HIV-2
Distance Distance
(A) Atom (A)
2.5 081 Asp-A25 3.0
2.9 082 Asp-A25 2.8
2.8 O61 Asp-B25 3.1
2.8 052 Asp-B25 2.9
3.3 O Gly-B27 3.3
2.9 N Asp-B28 2.8
3.2 O Wat-14 3.3
3.1 O Gly-B48 3.0
2.7 O Wat-3 2.6
3.0 O Gly-B27 3.3
3.2 O Gly-A27 3.0
2.6 O Wat-3 2.9
2.9 O Gly-A48 3.1
2.9 N Asp-A29 2.9
3.3 O Wat-16 3.3
Nevertheless, the hydrogen-bonding pattern of the
pseudosymmetric inhibitor is the same. A comparison of
the binding pattern of an asymmetric substrate analog
inhibitor, CGP 53437 (structure determined to 2.1 A
resolution in complex with HIV-1 protease; J Priestle et
al., unpublished data), with that of CGP 53820 is shown
in Fig. 4. The symmetric inhibitor is accommodated in
the active site with an inverted stereochemical center N
of the P1' cyclohexyl group as compared with the C of
the P1' phenyl group of the asymmetric inhibitor CGP
53437. The geometry of the hydrazine moiety of CGP
53820 is the same as that found in similar small molecule
structures. This inversion leads to a reorientation of the
peptide bond which can consequently form the same
hydrogen bonds with the enzyme as a substrate presum-
ably would. The inverted stereochemical orientation of
the P1' chain had been predicted by molecular modeling.
Modeling
The X-ray structure of the complex between the
inhibitor MVT-101 and HIV-1 protease [29] was kindly
provided by A Wlodawer and is now available from the
Brookhaven Protein Data Bank [30] (accession number
4HVP), and was taken as the basis for modeling prior to
our own crystallographic investigations. Following the
basic assumption that a hydrogen-bonding pattern mak-
ing use of all amide groups is conserved, CGP 53820 was
docked into the active site of the protein. We selected the
conformation of the hydrazine moiety as it is found in
crystal structures of comparable small molecules from the
Cambridge structural database [31] as a basis for our
modeling. However, due to the lack of appropriate force-
field parameters for hydrazine, the tetrahedral nitrogen
was replaced by an sp3 carbon for the calculations. A
Monte Carlo conformational search and substructure
minimization was performed on this complex structure
using the program MacroModel [32]. In Fig. 5, the low-
est energy structure is superimposed on the X-ray
structure of CGP 53820 in the complex. Clearly there is
a good deal of similarity between the predicted and the
experimentally determined structures.
Structural comparison of HIV-1 and HIV-2 CGP 53820
complexes
An overall comparison of the active sites of the HIV-1
and HIV-2 protease CGP 53820 complex structures is
shown in Fig. 6. The inhibitor and active sites are very
similar, but small differences in the architecture of the
P1 and P1' pockets can be observed. In addition,
Fig. 4. Stereo illustration comparing
CGP 53820 (green) in the active site of
HIV-1 protease (red) with CGP 53437
(yellow), a substrate analog, bound to
HIV-1 protease (blue). Potential hydro-
gen bonds (distoN<3.5 A) between the
inhibitors and enzymes are indicated
with dashed lines. A tightly bound water
molecule (WAT) forms hydrogen bonds
with both the inhibitor and 'flap'
residues of the enzyme. Despite the
direction reversal in the pseudosymmet-
rical CGP 53820, the hydrogen-bonding
scheme remains intact.
Fig. 5. Stereo illustration of the pre-
dicted conformation of CGP 53820
(yellow) superimposed with the crystal-
lographically determined conformation
of the inhibitor (red) bound in the active
site of HIV-1 protease (A-chain, blue;
B-chain, purple).
----
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conservative amino acid exchanges in the P2/P2' pockets
contribute to the structural differences of the two
enzymes. In the active site of HIV-2 protease, two amino
acid replacements, Val32-Ile and Ile47--Val, are
observed with respect to the HIV-1 protease. These
exchanges are complementary and compensate for the
loss/gain of binding activity because the side chains of
these residues are found on opposite sides of the P2 and
P2' pockets (Fig. 7a). The fact that the very same
Val-Ile exchanges have also been observed as single
mutations in HIV-1 protease after selection with certain
HIV protease inhibitors in vitro shows that these amino
acid positions can also determine drug resistance without
concomitant loss of enzyme activity. Although the active
site P2 and P2' pockets remain unchanged in the total
volume that they provide, their orientation is slightly
Fig. 6. Stereo illustration of the binding
of CGP 53820 (green) to HIV-1 protease
(red) superimposed with HIV-2 protease
(blue) in complex with CGP 53820
(yellow).
Fig. 7. Stereo illustrations of the binding
pockets of HIV-1 protease (red) com-
plexed with CGP 53820 (green) super-
imposed with HIV-2 protease (blue)
complexed with CGP 53820 (yellow).
(a) The sequence changes Val32<-l1le
and lle47*--Val in the P2 binding pocket
compensate for each other extremely
well as shown by the packing of their
van der Waals surfaces. (b) The
sequence change Val82-l1e in the
B-chain allows tighter packing against
the cyclohexyl moiety of CGP 53820,
but causes a significant change in the
conformation of the cyclohexyl moiety
relative to the complex with HIV-1 pro-
tease. (c) In contrast to the P' pocket,
the sequence change Val82*->lle in the
P1 pocket causes only minor changes in
the conformation of CGP 53820. A slight
rotation of the phenyl ring is accompa-
nied by a deflection of the Cy atom of
Pro81 from the + to the - conformation.
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changed. This might explain differences in binding affin-
ity between the two enzymes towards inhibitors contain-
ing bulkier residues binding in the P2/P2' subsites.
Analogously, a larger leucine side chain appears to fit
more comfortably in the P2 subsite of HIV-2 protease
than of HIV-1 protease [21]. In the case of CGP 53820,
which has a relatively small valine side chain in the
P2/P2' pockets, the influence on binding due to the
Ile32--Val and Val47-Ile changes is negligible.
The loop formed by residues 79-84, which covers part of
the P1/P1' pockets and harbors the cyclohexyl moiety of
the inhibitor, differs in the two structures. In the HIV-1
protease structure this loop in the B-chain moves by up
to 2.5 A out of the symmetric position to optimally
accommodate the bulky cyclohexyl group of the
inhibitor. This is in contrast to the HIV-2 protease struc-
ture which maintains good C2-symmetry within the loop
(Figs 3b, 7b). Mulichak et al. [16] have also seen move-
ment of this loop in HIV-2 protease when it is com-
plexed with the asymmetric inhibitor U92163. Apart
from these changes, the two structures are very similar. It
has been suggested that HIV-1 protease may have a pref-
erence for larger hydrophobic residues in the P1/P1' sub-
sites due to the smaller valine in position 82 of its loop as
compared with the bulkier isoleucine in position 82 of
HIV-2 protease [23]. This can be explained by the struc-
tures described here. The inhibitor CGP 53820 has a
bulky cyclohexyl side chain that binds in the P1' pocket.
In the HIV-2 protease-inhibitor structure, the cyclohexyl
group is rotated slightly towards the flap (by about a 100
rotation), as compared with the position in the HIV-1
structure (Fig. 7b), due to the C8 atom of the Ile82 side
chain of the protease. The consequence is that the whole
loop, residues 80-83, remains in a conformation that is
similar to the conformation of the loop around residue
80 in the C 2-symmetric subunit. In contrast, in the
HIV-1 protease structure this loop can easily accommo-
date the bulky side chain of the inhibitor and therefore
binding energy might be gained for CGP 53820. This
view is also supported by the differences between the
experimentally determined inhibition constants of CGP
53820 for the two HIV proteases, (9 nM for HIV-1 and
53 nM for HIV-2 protease). The effects of Ile82 on the
P1 specificity pocket where the phenyl side chain of
CGP 53820 binds are much more subtle (Fig. 7c). The
phenyl ring of the inhibitor is only rotated by a fewT
degrees and the relative position of the C-y in the Pro81
side chain changes due to steric hindrance caused by the
inhibitor's phenyl ring.
The structural differences in the two enzymes described
above might explain the observed differences in binding
affinities of CGP 53820 for HIV-1 and HIV-2 proteases.
Biological implications
Since the identification of HIV as the etiologic
agent responsible for the development of AIDS,
most research effort has concentrated on the
sub-type HIV-1. The less pathogenic subtype,
HIV-2, has only recently attracted more interest as
it has been shown to be responsible for the accel-
erated spread of AIDS in India and East Asia.
The factors that determine the reduced patho-
genicity of HIV-2 compared with HIV-1 are still
not clear, but investigation of differences between
the two subtypes may shed light on this question.
Although there is little overall sequence identity
between the virus genomes, the pol genes of both
viruses are highly conserved. The proteases of the
two subtypes show approximately 50% sequence
identity at the amino acid level and this translates
into functional similarities. This can be seen in
the cross-reactivity of the two enzymes with their
respective viral substrates [20]. Furthermore, pro-
teases can cleave peptide substrates that mimic
the cleavage site within the precursor protein of
either virus subtype. Nevertheless, clear differ-
ences in substrate affinities can be measured with
peptide substrates. These differences are also
reflected in the different susceptibilities of the two
enzymes towards protease inhibitors. Most inhib-
itors show differences in their inhibition constants
of greater than a factor of five towards the two
enzymes [17,22]. Our structural analyses of CGP
53820 in complex with HIV-1 and HIV-2 protease
allow the interpretation of these differences at the
molecular level and should facilitate the design of
inhibitors that are equipotent with respect to the
two enzymes.
Furthermore, the information gained by this
analysis may help in the design of inhibitors that
do not easily trigger the development of drug-
resistant mutants. This hope is based on the fact
that some of the point mutations (for example,
Va132-Ile) that confer drug resistance on HIV-1
result in the same amino acid as that present in
the homologous position in HIV-2 protease.
Materials and methods
Preparation of HIV- 1 and HIV-2 protease
High-level expression of HIV-I protease was achieved in an
adapted T7 RNA polymerase system and will be described in
detail elsewhere (Andreansky et al., personal communication).
Escheridlia coli cells (strain BL21 DE3) were transformed with
an expression plasmid harboring a 390 base pair DNA fragment
which codes for the HIV-1 protease (bru isolate). The mature
HIV-1 protease sequence is preceded by an initiator methion-
ine and an additional 20 amino acids upstream derived from a
gag-pol transframe protein. The protease C terminus is created
by a translational termination codon.
Enzyme expressed in bacteria is purified from intracellular
inclusion bodies isolated from isopropyl -D-thiogalacto-pyra-
noside (IPTG)-induced cells. E. coli cells are sonicated and the
inclusion bodies are separated from the cytoplasmic fraction
by centrifugation at 14000 rpm for 30 min at 4C. The pellet
is then resuspended in 0.05 M Tris-HCl buffer, pH 8.0,
Inhibitor complexes of HIV-1 and HIV-2 proteases Priestle et al.
containing 5 mM EDTA, 0.05 M NaCI, and centrifuged a
second time. The resultant pellet is further purified by resus-
pension in a minimal volume of 0.2 M Tris-HCI buffer,
pH 7.0, containing 0.1 M phosphate, 0.5% 3-mercap-
toethanol, 0.2 M NaCl and 0.01 M EDTA. This volume is
diluted into 9 M urea in the same buffer and dialyzed against
51 of Tris-HCl buffer, pH 7.5, 4 mM EDTA, 0.1% 3-mer-
captoethanol and 20% glycerol. Three changes of dialysis
buffer are made in a 6 h time period. The precipitate which
forms during dialysis is pelleted by centrifugation and solubi-
lized in 9 M urea (the precipitate still contains large quantities
of the protease). The solution is dialyzed as described above
and centrifuged again. Peptide contaminants from the pooled
supernatants are partially removed by chromatography with a
QAE-Sephadex A 25 column, equilibrated with 0.05 M
borate buffer, pH 8.5, containing 0.05% P3-mercaptoethanol.
After the QAE-Sephadex column the samples were concen-
trated approximately 10-fold by ultrafiltration using an Amricon
(Beverly, MA, USA) UM 2 membrane. The pH was adjusted
to 5.0 and samples were slowly applied at 4C to 9x2.2 cm 2
affinity columns equilibrated with 50 mM acetate pH 5, 0.1%
P-mercaptoethanol, 2 mM EDTA, 0.01% sodium azide. The
column was washed with equilibration buffer and the proteases
eluted with 50 mM borate buffer, pH 10.2 containing 0.1%
-mercaptoethanol, 0.01% azide, 2 mM EDTA and 40%
glycerol. The collected fractions were immediately mixed with
1 M acetate buffer pH 5 (resulting in a final pH of 6). Activities
of individual fractions were measured as described earlier [33],
fractions were pooled, concentrated and stored at -20°C. To
obtain a convenient affinity column, the peptide inhibitor
Ser-Gln-Asn-Tyr*-Pro-Ile-Val-Gln-Lys-Gly-CONH 2 (where
* indicates a flly reduced peptide bond, CH2-N) was coupled
to Affigel 10 (BioRad) by the procedure recommended by the
manufacturer. Alternatively, the peptide BocPhe*-Phe-Ile-
Phe-Gly-Lys-CONH 2 was directly synthesized on macrop-
orous beaded cellulose support (P Strop et al., unpublished
data) and used for affinity purification with basically the same
experimental protocol. The solution was then concentrated
using an Amicon YM 3 membrane and used directly for Ki
measurements. The purity of the enzyme preparation is moni-
tored by SDS-PAGE electrophoresis and ion-exchange chro-
matography using a Pharmacia FPLC Mono S 5/5 column.
Amino acid analysis and N-terminal sequencing confirmed that
the protease was processed correctly at the N terminus.
HIV-2 protease (rod isolate) was expressed, purified and
assayed using essentially the same procedures as described for
HIV-1 protease. Experimental details will be published else-
where (P Strop et al., unpublished data).
Enzyme-inhibitor assay (IC50so of CGP 53820)
The IC 50 of CGP 53820 against HIV-1 and HIV-2 protease
were determined using the peptide substrate His-Lys-Ala-Arg-
Val-Leu-Nph-Glu-Ala-Nle-Ser-NH 2 (Nph, nitro-phenylala-
nine; Nle, norleucine) as described by Pennington et al. [34].
The cleavage reactions were monitored by reverse-phase high-
performance liquid chromatography analysis. Product forma-
tion was used to quantify the results. The assay conditions for
HIV-1 and HIV-2 protease are described in [21]. The IC50
values are the mean of three independent determinations.
Inhibitor preparation
The synthesis of CGP 53820 has been described previously
[28]. Briefly, 1'(S) (t-butyloxycarbonyl)amino-2-phenylethy-
loxirane was reacted with cyclohexylmethyl t-butyl carbazate
to yield the protected dipeptide isostere. Deprotection fol-
lowed by double acylation using N-acetyl-(L)-valine gave the
final product CGP 53820. The inhibitor was shown to be
homogeneous by standard analytical methods [28].
Crystallization of protein-inhibitor complexes
Crystals of the HIV-1 and HIV-2 inhibitor complexes were
grown by co-crystallization using the hanging-drop vapor-dif-
fusion method. The inhibitor was dissolved in dimethylsulfox-
ide (10 mg ml-1). A five-fold molar excess of the inhibitor was
added to a 2 mg ml - sample of the native enzyme which had
been previously dialyzed against 0.1 M sodium acetate buffer
(pH 5.4). The complex was crystallized as described previously
[29]. Typically, 15-30% saturated ammonium sulfate buffered
at pH 5.4 with 0.1 M sodium acetate was used as precipitant.
Droplets were prepared by diluting a small volume of the pro-
tein-inhibitor solution with an equal volume of the respective
15-30% saturated ammonium sulfate solution. Crystals
appeared in 1-2 weeks as small rods with typical dimensions of
0.1 mxO.1 mmx0.3 mm. Both types of crystal belong to the
space group P21 2121 with one dimer-inhibitor complex in the
asymmetric unit. Crystallographic parameters for both crystal
types are summarized in Table 3.
Data collection and data processing
Diffraction data were collected for both complexes using a
FAST area detector with graphite monochromated CuKot radi-
ation generated from an Enraf Nonius FR 571 rotating anode
source operating at 40 kV and 70 mA. A single crystal for each
data set was used and 0.1 ° frames with an exposure time of
120 s per frame were collected. The frames were processed
with the software MADNES [35] and subsequently with the
CCP4 program package [36] to provide the diffraction data
summarized in Table 3.
Structure solution of HIV- 1/CGP 53820
The crystal form appeared to be isomorphous with that of the
fully synthesized HIV-1 protease complexed with the inhibitor
MVT-101 [29]. The coordinates for this structure (accession
number 4HVP) were obtained from the Brookhaven Protein
Data Bank [30]. Molecular replacement using these coordinates
after stripping out the inhibitor and solvent molecules and
replacing the amino-butyric acid residues in the synthetic
Table 3. Data collection parameters for HIV-1 and HIV-2 proteases in
complex with CGP 53820.
HIV-1 HIV-2
Mr (monomer) 10764 10845
Space group P212121 P212121
a 52.0A 33.4A
b 59.3 A 64.2 A
c 61.8 A 99.5A
Volume 191 000ooo A3 213000 A3
VM 2.21 A3 Da- 1 2.46A3 Da- 1
Asymmetric unit content 1 HIV-1 PR dimer 1 HIV-2 PR dimer
Resolution 2.2 A 2.3 A
Rmerge (overall) 5.7% 5.1%
Rmerge (last shell) 22.6% 19.0%
(2.26-2.20A) (2.38-2.30 A)
Number of measurements 30789 39279
Number unique 10082 9517
Multiplicity 3.05 4.13
Completeness 99.4% 94.3%
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structure with the correct cysteine residues indeed gave a rota-
tion function peak only at the origin. The initial crystallo-
graphic R-factor was 0.395 to 2.8 A resolution. Initial
refinement was carried out without the inhibitor using the
least-squares program TNT [37]. Further refinement was also
carried out using the molecular dynamics program X-PLOR
[38] followed by more refinement with TNT. After isotropic
temperature-factor refinement had brought the R-factor down
to 0.236, an F-F c difference electron-density map was calcu-
lated and examined. Three of the top four peaks were parts of
the inhibitor which could easily be fitted in its entirety.
Although the enzyme possesses perfect two-fold symmetry in
solution, the electron density for the inhibitor was clearly asym-
metric, with a clear distinction between the flat benzyl group in
the P1 binding site and the more spherical density for the cyclo-
hexyl group in P1'. Other large positive peaks were interpreted
as solvent molecules if they were found in stereochemically
reasonable positions. No reference was made to the solvent
molecules found by [29]. The only large peaks not attributable
to either the inhibitor or solvent molecules were near the sulfur
atoms of cysteine residues A67 and B67 and the peptides
between 50 and 51 at the end of the flaps in both chains, imply-
ing concerted peptide flips. Minor sequence corrections were
made at this time (Argl4---Lys, Asn37---)Ser, Lys41--)Arg,
Pro63--Leu and Val64--le). Dictionary entries for ideal
stereochemistry for CGP 53820 were made for both TNT and
X-PLOR. About halfway through the refinement the original
X-PLOR amino acid topologies and parameters were replaced
with those of Engh and Huber [39]. Further refinement
brought forth more solvent molecules and a consistently large
peak near both Cys67 residues. Attempts to model residue 67
with valine or isoleucine, while fitting the side chain density
better (especially isoleucine), caused the main chain to become
distorted and showed weaker electron density. This was finally
interpreted as a -mercaptoethanol molecule attached covalent-
ly to Cys67. This interpretation fitted both the electron density
and the stereochemical restraints for the region. This was found
for Cys67 in both chains of the dimer. Nothing similar was
found for Cys95 in either chain. Extra density around this
residue was also found by Thanki et al. [40] who interpreted it
as oxidation of the cysteine residue to sulfenic acid.
Structure solution of HIV-2/CGP 53820
The structure of HIV-2 protease in complex with CGP 53820
was solved using molecular replacement techniques. The par-
tially refined structure of HIV-1 protease in complex with CGP
53820 was used as the trial structure. All protein residues were
included. The sequences of the two enzymes are identical in 48
places. Leul9 was changed to a proline. For the remaining
residues the side chains were either truncated to alanine (48
cases) or to glycine (2 cases). The inhibitor was also retained.
The single conserved water molecule in the active site was kept,
but all others were discarded. The rotation was calculated using
the program POLARRFN [36] and gave a maximum at ot=0°,
{=75 ° and y=18 0 (=37.5 °, =0, K=180°) that was 5.1cr
above the mean and 1.6 times larger than the highest noise
peak. A second peak 98.7% as high as the first was found 178.3 °
away from the first reflecting the C2-symmetry of the enzyme.
The translation function was calculated using TFSGEN [36].
The highest peak suggested a translation of Ax=3.16 A,
Ay=29.31 A, and Az=3.95 A, and was 12.3cr above the mean
and 1.7 times larger than the highest noise peak. The initial
crystallographic R-factor after rotating and shifting the trial
model into the unit cell was 0.53. Molecular replacement was
also performed using Patterson correlation [41] as incorporated
into the program X-PLOR [38]. This gave a rotation function
solution of =2° , 3=73 ° and y=17 9 .4° (o=143.5 ° ,
b=-178.7 ° , K=178.9° , peak 5.4r above the mean) and a trans-
lation result of Ax=3.75 A, Ay=29.48 A, and Az=3.05 A (peak
10.3cr above the mean). Applying this rotation and translation
to the trial model gave a crystallographic R-factor of 0.521.
Molecular dynamics refinement (using X-PLOR [38]) of the
enzyme without the inhibitor brought the R-factor down to
0.319. At this point an F-F c difference electron-density map
was calculated and the sequence corrected for HIV-2 protease
and the inhibitor CGP 53820 was also first fitted to the electron
density. Refinement continued with alternating cycles of mol-
ecular dynamics refinement and temperature-factor refinement
followed by examination/manual correction of the protein
structure and addition of solvent molecules. One large correc-
tion was the repositioning of the inhibitor in the other direction
relative to how it was first fitted. Although CPG 53820 is quite
symmetric, the area around the hydroxyl group between P1 and
P1' is rather asymmetric (Fig. 3). Stereochemical distortions
here during refinement indicated that the molecule had initially
been fitted incorrectly. After refitting, both the fit to the elec-
tron density and the stereochemistry were improved. The final
refinement statistics are presented in Table 4. The only large
main-chain alteration was a peptide flip about the bond
between residues 50 and 51 in both chains. Two solvent peaks
were interpreted as SO42- ions because of the shapes of the
electron density, distances to potential hydrogen bond donors in
the protein, and the environments of the sites. Two corrections
had to be made to the X-PLOR dictionary of CGP 53820
during refinement. Analysis of crystal structures of related com-
pounds indicated that the N of the cyclohexane moiety should
be in a tetrahedral conformation, rather than planar. It also
proved necessary to include torsion angle restraints within the
cyclohexane ring in order to maintain a chair conformation. At
2.3 A resolution it was not possible to determine the confor-
mation of the ring based on the electron density alone.
Coordinates for the HIV-1 and HIV-2 proteases, both com-
plexed with the pseudosymmetric inhibitor CGP 53820, are
being deposited with the Brookhaven Protein Data Bank [30].
Table 4. Structural parameters after refinement of the complexes of
CGP53820 and the proteases from HIV-1 and HIV-2.
HIV-1 HIV-2
Resolution 6.0-2.2A 6.0-2.3A
Number of reflections 9515 8879
Rf (all reflections) 0.144 0.138
Rmsd bond lengths 0.012 0.012A
Rmsd bond angles 1.83 ° 2.00°
Rmsd improper angles 1.42 ° 1.53'
Atoms in HIV dimer 1516 1510
CGP53820 41 41
Solvent 145 194
Misc. 8 (2 x BME) . 10 (2 x 504 )
Total atoms 1710 1755
Local symmetry
Rmsd all Cas 0.720A (99 Cs) 0.527 A (99 Cas)
Rmsd reduced Coa set 0.469A (93 Cas) 0.430A (97 Cas)
Excluded C0s 16,17,39,80,81,82 40,67
X angle 178.4° 1 79.8°
Abbreviations: Rmsd, root mean square deviation from ideal; BME,
p-mercaptoethanol. is the rotation relating the A- and B-chains of the
dimer.
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